HGF derived from cancer-associated fibroblasts promotes vascularization in gastric cancer via PI3K/AKT and ERK1/2 signaling

XUSHENG DING1,2*, WENQI XI1*, JUN JI2, QU CAI2, JINLING JIANG1, MIN SHI1, YINGYAN YU2, ZHENGGANG ZHU1,2 and JUN ZHANG1,2

Departments of 1Oncology and 2Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China

Received February 14, 2018; Accepted June 13, 2018

DOI: 10.3892/or.2018.6500

Correspondence to: Professor Jun Zhang, Department of Clinical Oncology, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin Er Road, Shanghai 200025, P.R. China
E-mail: junzhang10977@sjtu.edu.cn

*Contributed equally

Key words: cancer-associated fibroblasts, gastric cancer, hepatocyte growth factor, angiogenesis

Abstract. Cancer-associated fibroblasts (CAFs) are predominate cells in tumor stroma and play a key role in tumor progression. Hepatocyte growth factor (HGF) is a cytokine mainly derived from fibroblasts. In the present study, we reported that HGF significantly promoted angiogenesis of human umbilical vein endothelial cells (HUVECs) and vasculogenic mimicry (VM) formation of gastric cancer cells, respectively, by increasing cell proliferation and migration. In addition, mosaic vessels formed by HUVECs and gastric cancer cells were also increased with treatment of recombinant human HGF and conditioned medium from CAFs. The opposite results were achieved in HGF-neutralized groups. In accordance with these observations, we determined that phosphorylation of AKT and ERK1/2 were upregulated in HUVECs and gastric cancer cells with HGF treatment and co-culture with CAFs. Both AKT inhibitor LY294002 and ERK1/2 inhibitor U0126 reduced the ability of angiogenesis and VM formation, as well as mosaic vessel formation induced by HGF. Gene Set Enrichment Analysis and correlation analysis were performed to confirm our findings. In conclusion, CAF-derived HGF promotes angiogenesis, VM and mosaic vessel formation via PI3K/AKT and ERK1/2 signaling in gastric cancer and HGF may serve as a potential therapeutic target for cancer anti-vascular treatment.

Introduction

Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide in the past decades (1,2). Despite the improvement of surgical intervention and adjuvant chemotherapy, the 5-year overall survival rate in GC patients is less than 30% (3,4). Therefore, a better understanding of molecular and cellular mechanisms of GC tumorigenesis and metastasis will assist emergence of preferable therapeutic strategies.

Solid tumors are composed of tumor cells and tumor stroma, including the extracellular matrix (ECM), endothelial cells and a large amount of fibroblasts (5). Following tumorigenesis, local normal fibroblasts are transformed to cancer-associated fibroblasts (CAFs) under the influence of cancer cells (6). CAFs are distinguishable from their normal counterparts with the enhanced expression of alpha-smooth muscle actin (α-SMA) and fibroblast activation protein (FAP). Other markers of CAFs reported are fibroblast specific protein-1 (FSP -1), stromal cell-derived factor -1 (SDF -1) and platelet-derived growth factor receptor-α (PDGFRα) (7,8). Accumulating evidence has indicated a significant role of cytokines secreted by CAFs in mediating tumor growth and metastasis (9-11). Among these stromal cytokines, HGF is expressed mainly in CAFs and acts on c-Met-positive cancer cells in the tumor microenvironment (12,13). Interactions between CAFs and cancer cells activate the HGF/c-Met signaling pathway and thus trigger a number of downstream oncogenic signaling cascades, such as PI3K/AKT and ERK1/2, leading to tumor growth and metastasis (14). Recent studies have reiterated the promoting effect of fibroblast-derived HGF on tumor progression and suggest it to be a potential therapeutic target (15-17).

Growth of a solid tumor relies on blood vessels to transport nutrients to satisfy its metabolic demands (18), particularly when the diameter extends beyond 2 mm (19). Endothelium-dependent vessels are the predominant vascularization in solid tumors and an anti-angiogenesis strategy has been widely used in the treatment of various types of malignant tumors. In addition, as an endothelium-independent pattern, vasculogenic mimicry (VM) tubes formed by cancer cells also participate in vascularization (20,21). VM can serve...
as an internal blood supply network to contribute to tumor progression and has been revealed to be strongly associated with a poor prognosis in gastric cancer (18,22). Mosaic vessels, which are formed by endothelial cells accompanied by tumor cells (23,24), also reveal their significant involvement in tumor growth and metastasis (25). It has been reported that HGF promotes endothelium-dependent angiogenesis in pancreatic cancer and VM formation in hepatocellular carcinoma (26,27), while the specific mechanism has not been well elucidated. In our previous study, we confirmed the existence of VM and mosaic vessels in gastric cancer (18,28). In the present study, we further explored the effects of CAF-derived HGF on angiogenesis, VM and mosaic vessel formation in gastric cancer and illuminate their underlying mechanisms.

Materials and methods

Cell lines and culture. The human GC cell lines SNU16, MKN74, BGC823, AGS, SGC7901, MGC803 and NCI-N87, and normal GES1 gastric mucosal cells were provided by Shanghai Institute of Digestive Surgery (Shanghai, China). HUVECs were purchased from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). These cells were routinely maintained and cultured. Primary cancer-associated fibroblasts (CAFs) were isolated from a GC patient undergoing radical gastrectomy on June 14, 2017 at the Department of Surgery, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University (29). The patient did not receive preoperative treatment. To maintain the characteristics of primary cells, CAFs passedaged for up to 10 population doublings were used in the subsequent experiments. All the cells were cultured at 37°C in 5% CO₂ with RPMI-1640 medium (Genom, Hangzhou, China) containing 10% fetal bovine serum (FBS; Gibco-BRL, Grand Island, NY, USA). The study was approved by the Ruijin Hospital Ethics Committee of Shanghai Jiaotong University School of Medicine and written informed consent was provided by the patient.

Survival analysis with an online database. Survival analysis of 378 GC patients with survival data from TCGA (The Cancer Genome Atlas) database according to HGF expression was performed with online website OncoLnc (http://www.oncolnc.org/) and the lower percentile was set to be equal to the upper percentile. The Kaplan-Meier plotter (http://www.kmplot.com/analysis/) was used to assess the effect of HGF (Affymetrix ID: 209961_s_at, 210755_at, 210997_at, 210998_s_at) on the survival of 876 GC patients from Gene Expression Omnibus (GEO) database and patients were split by auto select best cutoff.

Gene Set Enrichment Analysis (GSEA) and correlation analysis. RNA-seq of 415 patients from Stomach Adenocarcinoma (TCGA, Provisional) was downloaded from cBioPortal platform (http://www.cbioportal.org/). Microarray profiles of 300 GC patients were downloaded from the GEO database (https://www.ncbi.nlm.nih.gov/geo/). Gene Set Enrichment Analysis was performed with GSEA 3.0 software (Broad Institute, Cambridge, MA, USA) and the number of permutations was set to 1,000. Corresponding gene sets were downloaded from the Molecular Signatures Database v6.1 (http://software.broadinstitute.org/gsea/msigdb/index.jsp). The mean value of gene (containing different Affymetrix IDs) expression was used for correlation analysis.

Immunofluorescence. Briefly, CAFs and frozen sections of GC tissues were fixed in 4% neutralized formaldehyde followed by permeabilization with 0.5% Triton X-100 (Sigma-Aldrich; Merck KGaA, Taufkirchen, Germany). Cells and frozen sections were blocked with 3% bovine serum albumin (BSA) and then incubated at 4°C overnight with primary antibodies for α-SMA (dilution 1:100; cat. no. ab5694; Abcam, Cambridge, MA, USA), FAP (dilution 1:100; cat. no. sc-71094; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and CD31 (dilution 1:100; cat. no. sc-65260; Santa Cruz Biotechnology). Then, the CAFs and frozen sections were stained with appropriate Alexa dye-conjugated secondary immune reagents and subjected to Olympus BX53 microscope (fluorescence; Olympus Corp., Tokyo, Japan) (magnification, x200) and EVOS™ FL Color Imaging System (fluorescence; Thermo Fisher Scientific, Inc., Waltham, MA, USA) (magnification, x40), respectively.

ELISA assay. GC cells (1x10⁵), CAFs (1x10⁵) and HUVECs (1x10⁵) were cultured in 2 ml of RPMI-1640 complete medium for 36 h. The conditioned medium (CM) was collected and centrifuged at 12,000 x g for 10 min to remove cell debris. The levels of HGF in supernatants of GC cells, HUVECs and CAFs were detected by ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.

Cell proliferation. Cell proliferation was performed using Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, Kumamoto, Japan). MGC803 and HUVECs were suspended in supernatants with different treatments as indicated and plated in a 96-well plate at 1,000 cells/well. Cell proliferation was assessed every 24 h at an absorbance of 450 nm using spectrophotometry (BioTek Instruments, Winooski, VT, USA).

Cell migration. MGC803 cells (5x10⁴) and HUVECs (5x10⁴) suspended in 200 µl serum-free RPMI-1640 medium were cultured in the upper chamber with or without CAFs (2x10⁴) suspended in 600 µl RPMI-1640 medium containing 10% FBS in the lower chamber for 15 h using Transwell chambers (8 µm; Corning Costar, Corning, NY, USA). Then GC cells and HUVECs were fixed using 4% neutralized formaldehyde and stained with 0.5% crystal violet. The migrated cells in the lower chambers were photographed using Olympus BX50 light microscope (Olympus Corp.; magnification, x200) and counted.

Quantitative real-time PCR (qRT-PCR). Total RNA extracted from cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was reversely transcribed to cDNA using a reverse transcription kit (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. Gene expression was quantified by qRT-PCR with SYBR-Green (Applied Biosystems; Thermo Fisher Scientific, Inc.) and ABI Prism 7900HT sequence detection system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The relative mRNA levels were evaluated based on the Ct values and
Table I. PCR primers.

<table>
<thead>
<tr>
<th>Genes</th>
<th>Forward (5'-3')</th>
<th>Reverse (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>HGF</td>
<td>GGGCTGAAAGAATGGGATCA</td>
<td>TTGATTGGTGGTGGCTTCA</td>
</tr>
<tr>
<td>MET</td>
<td>GGTCTTTCTGTGCTGAA</td>
<td>GGCATGACCGTTCTGAGAT</td>
</tr>
<tr>
<td>MMP1</td>
<td>GGCGCTTGGATGTACCTGAC</td>
<td>TGTCAACGCTTTTGAGGTTT</td>
</tr>
<tr>
<td>MMP2</td>
<td>GATACCCCTTTGACGTTAGG</td>
<td>CCTTCTCCAAAGGTCCATGAC</td>
</tr>
<tr>
<td>CDH5</td>
<td>AAGCGTGAGTCGCAAGAT</td>
<td>TCTCAGGGTTCGCAAGTG</td>
</tr>
<tr>
<td>MMP2</td>
<td>GGTCTTTCTGTGCTGAA</td>
<td>GATACCCCTTTGACGTTAGG</td>
</tr>
<tr>
<td>TFF1</td>
<td>TCTTGCGCCGTAGCTAGC</td>
<td>CATGTGTCGCTAAAGCAAGCA</td>
</tr>
<tr>
<td>VEGFR2</td>
<td>GTGATCAGGAATAGCAGACTTGGAG</td>
<td>GGCATCACGGCAGATGGTTC</td>
</tr>
<tr>
<td>GAPDH</td>
<td>ACAACTTTTGGATCGTGGGAGG</td>
<td>GCCATCACGGCAGATGGTTC</td>
</tr>
</tbody>
</table>

GAPDH was used as an internal control. The PCR primers used for the genes in the present study are listed in Table I.

Western blotting. Western blotting was performed as previously described (18). In brief, HUVECs and MGC803 cells were lysed using the RIPA buffer (Thermo Fisher Scientific, Inc.) after stimulation with recombinant human HGF (50 ng/ml; cat. no. ab105061; Abcam) for 1 h. In groups of inhibition, HUVECs and MGC803 cells were pretreated with LY294002 (50 µM; cat. no. 9901) and U0126 (20 µM; cat. no. 9903; both from Cell Signaling Technology, Inc., Danvers, MA, USA) for 6 h before they were co-cultured with primary CAFs. HUVECs were lysed using the RIPA buffer (Thermo Fisher Scientific, Inc.) after stimulation with recombinant human HGF (50 ng/ml; cat. no. ab105061; Abcam) for 1 h. In groups of inhibition, HUVECs and MGC803 cells were pretreated with LY294002 (50 µM; cat. no. 9901) and U0126 (20 µM; cat. no. 9903; both from Cell Signaling Technology, Inc., Danvers, MA, USA) for 6 h before they were co-cultured with primary CAFs. HUVECs were lysed using the RIPA buffer (Thermo Fisher Scientific, Inc.) after stimulation with recombinant human HGF (50 ng/ml; cat. no. ab105061; Abcam) for 1 h. In groups of inhibition, HUVECs and MGC803 cells were pretreated with LY294002 (50 µM; cat. no. 9901) and U0126 (20 µM; cat. no. 9903; both from Cell Signaling Technology, Inc., Danvers, MA, USA) for 6 h before they were co-cultured with primary CAFs. HUVECs were lysed using the RIPA buffer (Thermo Fisher Scientific, Inc.) after stimulation with recombinant human HGF (50 ng/ml; cat. no. ab105061; Abcam) for 1 h. In groups of inhibition, HUVECs and MGC803 cells were pretreated with LY294002 (50 µM; cat. no. 9901) and U0126 (20 µM; cat. no. 9903; both from Cell Signaling Technology, Inc., Danvers, MA, USA) for 6 h before they were co-cultured with primary CAFs. HUVECs were lysed using the RIPA buffer (Thermo Fisher Scientific, Inc.) after stimulation with recombinant human HGF (50 ng/ml; cat. no. ab105061; Abcam) for 1 h. In groups of inhibition, HUVECs and MGC803 cells were pretreated with LY294002 (50 µM; cat. no. 9901) and U0126 (20 µM; cat. no. 9903; both from Cell Signaling Technology, Inc., Danvers, MA, USA) for 6 h before they were co-cultured with primary CAFs. HUVECs were lysed using the RIPA buffer (Thermo Fisher Scientific, Inc.) after stimulation with recombinant human HGF (50 ng/ml; cat. no. ab105061; Abcam) for 1 h. In groups of inhibition, HUVECs and MGC803 cells were pretreated with LY294002 (50 µM; cat. no. 9901) and U0126 (20 µM; cat. no. 9903; both from Cell Signaling Technology, Inc., Danvers, MA, USA) for 6 h before they were co-cultured with primary CAFs. HUVECs were lysed using the RIPA buffer (Thermo Fisher Scientific, Inc.) after stimulation with recombinant human HGF (50 ng/ml; cat. no. ab105061; Abcam) for 1 h. In groups of inhibition, HUVECs and MGC803 cells were pretreated with LY294002 (50 µM; cat. no. 9901) and U0126 (20 µM; cat. no. 9903; both from Cell Signaling Technology, Inc., Danvers, MA, USA) for 6 h before they were co-cultured with primary CAFs. HUVECs were lysed using the RIPA buffer (Thermo Fisher Scientific, Inc.) after stimulation with recombinant human HGF (50 ng/ml; cat. no. ab105061; Abcam) for 1 h. In groups of inhibition, HUVECs and MGC803 cells were pretreated with LY294002 (50 µM; cat. no. 9901) and U0126 (20 µM; cat. no. 9903; both from Cell Signaling Technology, Inc., Danvers, MA, USA) for 6 h before they were co-cultured with primary CAFs. HUVECs were lysed using the RIPA buffer (Thermo Fisher Scientific, Inc.) after stimulation with recombinant human HGF (50 ng/ml; cat. no. ab105061; Abcam) for 1 h. In groups of inhibition, HUVECs and MGC803 cells were pretreated with LY294002 (50 µM; cat. no. 9901) and U0126 (20 µM; cat. no. 9903; both from Cell Signaling Technology, Inc., Danvers, MA, USA) for 6 h before they were co-cultured with primary CAFs.
high HGF expression was found to be associated with a worse OS in GC patients. Collectively, this indicated that HGF was predominantly secreted by CAFs and negatively correlated with OS in GC patients.

CAF-derived HGF promotes tube formation of HUVECs, VM formation of GC cells and mosaic vessel formation in vitro. Angiogenesis and VM tubes are vital to tumor progression and HGF has exhibited its promoting effects on angiogenesis in pancreatic cancer and VM formation in hepatocellular carcinoma (26,27,30). Therefore, we next examined the effects of HGF on angiogenesis and VM formation in gastric cancer. Conditioned medium (CM) of CAFs with or without HGF neutralization and recombinant human HGF were subjected to HUVECs and MGC803 cells. Both CAF-CM and recombinant human HGF promoted angiogenesis of HUVECs and VM formation of MGC803 cells, while HGF neutralization significantly suppressed the stimulatory effect of CAF-CM on HUVECs and MGC803 cells (Fig. 2A). These results indicated that CAF-derived HGF promoted angiogenesis and VM formation in gastric cancer.

Tube formation is associated with cell proliferation and migration, thus we evaluated the tumor-promoting ability of HGF. The cell proliferation of HUVECs and MGC803 cells were increased in the CAF-CM groups and decreased in the HGF neutralization groups (Fig. 2B). To better mimic in vivo environments, we build an in vitro co-culture system (Fig. 2C). Migration assays were performed in a co-culture system and the results revealed that both stimulation of recombinant human HGF and co-culture with CAFs increased the ability of cell migration, which was reversed by HGF neutralization (Fig. 2D). The results aforementioned indicated that CAF-derived HGF promoted endothelium-dependent angiogenesis and VM formation by increasing cell proliferation and migration.
Mosaic vessels, which are composed of endothelia and cancer cells, serve as a bridge to transfer nutrition during tumor growth. We ascertained the existence of mosaic vessels in gastric cancer in our previous study (28). Since we determined the increase in tubule-forming ability of both HUVECs and GC cells induced by HGF from CAFs, we wondered whether HGF promoted the formation of mosaic vessels. As shown in Fig. 2E, more mosaic vessel structures were observed in groups with treatment of recombinant human HGF and CAF-CM, and the promoting effects were reversed by neutralizing the antibody against HGF. The differences among groups were statistically analyzed and displayed as the number of tubules, number of intersections and number of MGC803 cells in mosaic vessels. These findings indicated that CAFs not only promoted angiogenesis of HUVECs and VM formation of gastric cancer cells, but also increased the number of mosaic vessels in gastric cancer.

**HGF from CAFs promotes angiogenesis of HUVECs and VM formation of GC cells via PI3K/AKT and ERK1/2 signaling.**
HGF expression was revealed to be positively correlated with microvessel density (MVD) quantified in gastric and colorectal cancer (31,32). As aforementioned, we demonstrated that HGF was mainly derived from CAFs compared with GC cells and HUVECs. To elucidate the correlation between CAFs infiltration and MVD, co-localization of α-SMA and CD31 was performed using frozen sections of GC tissues. As shown in Fig. 3A, CAFs (represented by α-SMA) were accompanied by endothelial cells (represented by CD31) to a great degree. This indicated that CAFs infiltration resulted in angiogenesis.

HGF has been revealed to bind to its receptor and then trigger a number of downstream signaling cascades, among which PI3K/AKT and ERK1/2 are associated with tumor angiogenesis and VM formation (33,34). The expression of p-AKT and p-ERK1/2 in HUVECs and MGC803 cells was upregulated with treatment of recombinant human HGF as well as in a co-culture system with CAFs, which was reversed by HGF neutralization (Fig. 3B). To determine whether CAF-derived HGF promoted angiogenesis and VM formation through PI3K/AKT and ERK1/2 signaling, the inhibitor of PI3K/AKT signaling, LY294002, and inhibitor of ERK1/2 signaling, U0126, were used to investigate the underlying mechanisms. As shown in Fig. 3C, the promoting effects of recombinant human HGF and CAF-CM on angiogenesis of HUVECs and
VM formation of MGC803 cells were significantly inhibited by LY294002 and U0126, respectively. Statistical analysis of the number of tubules and number of intersections among these groups confirmed the results (Fig. 3D and E). This indicated that both PI3K/AKT and ERK1/2 signaling participated in angiogenesis and VM formation induced by HGF in gastric cancer.

Multiple molecules have been reported to participate in angiogenesis and VM formation (21,35). To confirm the promoting effects of HGF on angiogenesis and VM formation and explore the underlying mechanisms, we investigated and determined that HGF could regulate the expression of angiogenesis-related gene, VEGFR2 and VM-promoting related genes, MMP1, MMP2, CDH5 (VE-cadherin) and TFPI2. As shown in Fig. 4A, these genes were upregulated in MGC803 cells with treatment of recombinant human HGF and co-culture with CAFs compared with the negative control and HGF neutralized groups, respectively. Moreover, we analyzed gene expression patterns using RNA-seq of 415 GC patients from the TCGA database and microarray profiles of 300 GC patients from the GSE62254 database, and found that HGF was positively correlated with these molecules, respectively (Fig. 4B). The correlation between HGF and angiogenesis was also analyzed by Gene Set Enrichment Analysis (GSEA) with the TCGA and GSE62254 databases, and the results revealed that genes positively correlated with angiogenesis were enriched in HGF-high expression samples (Fig. 4C).

Increasing evidence has indicated that epithelial-mesenchymal transition (EMT) could induce VM formation (36,37), thus, we subsequently explored the relationship between HGF and EMT by GSEA and found that genes positively correlated with EMT were also enriched in HGF-high expression samples (Fig. 4D). In conclusion, CAF-derived HGF promoted angiogenesis and VM formation via PI3K/AKT and ERK1/2 signaling and upregulated the expression of these processes-related genes in gastric cancer.
Inhibitors of PI3K/AKT and ERK1/2 signaling reduce mosaic vessels induced by CAF-derived HGF. Mosaic vessels are formed by the cooperation of endothelia and cancer cells. Since we demonstrated the inhibiting effects of LY294002 and U0126 on both angiogenesis of HUVECs and VM formation of GC cells, we next examined whether these inhibitors had the same influence on mosaic vessel formation. As shown in Fig. 5A, both recombinant human HGF and conditioned medium of CAFs increased the number of mosaic vessels, which was reversed by inhibition of PI3K/AKT and ERK1/2 signaling. The number of tubules, number of intersections and number of MGC803 cells in mosaic vessels in the CAF-CM group were significantly increased compared with the control groups and significantly decreased when treated with LY294002 and U0126 (Fig. 5B). These results indicated that CAF-derived HGF promotes mosaic vessel formation via both PI3K/AKT and ERK1/2 signaling.

Discussion

Cancer-associated fibroblasts have revealed their irreplaceable roles in maintaining malignancy of solid tumors through secreting various types of cytokines, among which HGF has been reported to facilitate tumorigenesis and tumor progression (17,38). HGF overexpression was revealed to be positively correlated with depth of invasion, lymph node metastasis, TNM stage and poor survival of patients with gastric cancer (39). We analyzed the survival data of GC patients from TCGA and GEO databases and confirmed the negative correlation between HGF expression and overall survival. In the present study, we determined that HGF originating from CAFs accelerated endothelium-dependent angiogenesis through promotion of HUVEC proliferation and migration, which was consistent with a previous study in pancreatic cancer (26). In a co-culture system, the migration ability of GC cells was enhanced through reciprocal interactions with CAFs, which, however, was inhibited by neutralizing antibody against HGF. Thus, we demonstrated that CAF-derived HGF also facilitated VM formation. Mosaic vessels are formed by both endothelia and cancer cells. Given that HGF increased the abilities of both HUVECs and MGC803 cell migration, we further investigated and confirmed the promoting effect of CAF-derived HGF on mosaic vessel formation. These results revealed that HGF promotes vascularization, namely angiogenesis, VM formation and mosaic vessel formation. Thus, it is reasonable to hypothesize that HGF derived from CAFs may facilitate tumor progression through promotion of angiogenesis, VM formation and mosaic vessel formation in the GC microenvironment.
As one of the hallmarks of cancer, tumor angiogenesis is positively correlated with tumorigenesis, tumor growth and metastasis, which has been demonstrated by an increasing number of studies (30,40). An anti-angiogenesis strategy has been applied to inhibit tumor progression in multiple types of cancers (41-43). However, cancer cells could evade inhibition of angiogenesis after an initial response to therapeutic strategies that target endothelial cells. Thus, vasculogenic mimicry, a cancer cell-dependent pattern associated with poor survival, has become a potential target for anticancer strategy (44). HGF exhibits its tumor-promoting effect through binding to its receptor, c-Met, and then triggering several oncogenic signaling cascades, among which PI3K/AKT and ERK1/2 signaling have been reported to regulate angiogenesis and VM formation (21,33,34). PI3K/AKT and ERK1/2 signaling pathways have been revealed to regulate the growth, survival, and migration of endothelial cells and thus promote angiogenesis (45). Suppressing the phosphorylation of VEGFR2 could reduce the activation of the PI3K/AKT and ERK1/2 signaling pathways and thus inhibit angiogenesis (46). ERK1/2 was revealed to be positively involved in hypoxia-induced VM formation (47), and PI3K/AKT inhibition suppressed VM formation of hepatocellular carcinoma cells (48). HGF has been reported to promote angiogenesis in pancreatic cancer and VM formation in hepatocellular carcinoma (26,27), and in the present study, we found the same effects of HGF in gastric cancer. To further investigate whether the promoting effects of HGF on angiogenesis and VM formation rely on PI3K/AKT and ERK1/2 signaling, specific inhibitors of the two signaling pathways were subjected to the following experiments. Both inhibition of PI3K/AKT and ERK1/2 signaling could decrease the tubule-like structures of angiogenesis induced by HUVECs and VM induced by MGC803 cells. Many genes have been reported to facilitate VM formation (33,34,49). In addition, we found that HGF increased the expression of VM-promoting genes, such as MMP1, MMP2, CDH5 (VE-cadherin) and TFPI2 in GC cells, which were confirmed by correlation analysis of 415 samples from the TCGA database and 300 samples from the GSE62254 database. Other molecules that could increase VM formation, such as MMP9, MT1-MMP and EphA2 were also positively correlated with HGF by correlation analysis using these databases. However, they were not upregulated in groups with stimulation of HGF (data not shown). Thus, we hypothesized that HGF could facilitate VM formation through, at least in part, upregulation of the expression of these VM-promoting genes. Given these results, we examined the influence of LY294002 and U0126 on mosaic vessel formation, and found that they both significantly decreased the number of mosaic vessels. These findings suggest that PI3K/AKT and ERK1/2 signaling also participate in mosaic vessel formation. In addition, there are some instructive points that warrant improvement in our experiments: i) in vivo experiments investigating the impact of CAF-derived HGF on angiogenesis, VM formation and mosaic vessel formation should be conducted; and ii) the characteristics of CAFs may be influenced by clinical features, like TNM stage, pathological type and status of HP infection, thus CAFs isolated from different pathological types, tumor stages, and HP infection status should be analyzed. Fortunately, both these aforementioned points will be addressed in our ongoing follow-up studies.

Collectively, CAF-secreted HGF promoted angiogenesis, VM formation and mosaic vessel formation in gastric cancer. Crosstalks between CAFs and HUVECs, as well as gastric cancer cells promoted HUVECs and gastric cancer cell migration, and thus accelerated the process of vascularization. However, these effects could be inhibited by suppressing PI3K/AKT and ERK1/2 signaling. These results indicated that CAF-derived HGF promotes vascularization via PI3K/AKT and ERK1/2 signaling in gastric cancer, and it may serve as a prognostic indicator and potential therapeutic target for cancer anti-vascular treatment.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Science Foundation of China (nos. 81672327, 81502013 and 81602411), the Program of Shanghai Academic/Technology Research Leader (no. 17XD1402600), the Program for Outstanding Medical Academic Leader and Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (no. 20161410), the Development Grant for Clinical Trial (no. SHDC12017X06), the SCORE Foundation (no. Y-MX2015-078) and the Shanghai Municipal Commission of Health and Family Planning (no. 20154Y496).

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

XSD, WQX and JZ conceived and designed the study. XSD, WQX, JJ and QC performed the experiments. XSD, WQX, JLJ and MS wrote the manuscript. YYY, ZGZ and JZ reviewed and edited the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

The study was approved by the Ruijin Hospital Ethics Committee of Shanghai Jiaotong University School of Medicine and written informed consent was provided by the patient.

Patient consent for publication

Not applicable.

Competing interests

The authors state that they have no competing interests.
References


47. Huang B, Xiao E and Huang M: MEK/ERK pathway is positively involved in hypoxia-induced vasculogenic mimicry formation in hepatocellular carcinoma which is regulated negatively by protein kinase A. Med Oncol 32: 408, 2015.